IRIS
SCARFO', LYDIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.760
AS - Asia 3.658
EU - Europa 3.594
SA - Sud America 906
Continente sconosciuto - Info sul continente non disponibili 301
AF - Africa 59
OC - Oceania 18
Totale 13.296
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.533
RU - Federazione Russa 1.940
SG - Singapore 1.254
CN - Cina 1.148
BR - Brasile 741
HK - Hong Kong 557
IT - Italia 536
SE - Svezia 339
VN - Vietnam 281
DE - Germania 170
FR - Francia 170
BD - Bangladesh 123
GB - Regno Unito 112
CA - Canada 103
AR - Argentina 73
FI - Finlandia 65
IN - India 59
MX - Messico 49
AT - Austria 38
EC - Ecuador 34
IQ - Iraq 33
NL - Olanda 33
PL - Polonia 33
ID - Indonesia 31
JP - Giappone 29
ES - Italia 26
IE - Irlanda 25
GR - Grecia 22
CO - Colombia 20
AU - Australia 18
TR - Turchia 18
ZA - Sudafrica 18
BE - Belgio 17
UA - Ucraina 16
VE - Venezuela 16
AE - Emirati Arabi Uniti 15
PK - Pakistan 15
JM - Giamaica 14
MY - Malesia 12
PY - Paraguay 12
HN - Honduras 11
SA - Arabia Saudita 11
TN - Tunisia 10
IL - Israele 9
NP - Nepal 9
CR - Costa Rica 8
MD - Moldavia 8
LT - Lituania 7
MA - Marocco 7
UZ - Uzbekistan 7
KE - Kenya 6
NI - Nicaragua 6
NO - Norvegia 6
ET - Etiopia 5
GT - Guatemala 5
JO - Giordania 5
PH - Filippine 5
TT - Trinidad e Tobago 5
BB - Barbados 4
BH - Bahrain 4
DK - Danimarca 4
KZ - Kazakistan 4
LU - Lussemburgo 4
PA - Panama 4
SN - Senegal 4
SV - El Salvador 4
TH - Thailandia 4
AL - Albania 3
AZ - Azerbaigian 3
CH - Svizzera 3
CL - Cile 3
CZ - Repubblica Ceca 3
EG - Egitto 3
KR - Corea 3
LB - Libano 3
LV - Lettonia 3
PE - Perù 3
PR - Porto Rico 3
UY - Uruguay 3
AM - Armenia 2
DO - Repubblica Dominicana 2
GD - Grenada 2
GE - Georgia 2
IR - Iran 2
KH - Cambogia 2
KW - Kuwait 2
MQ - Martinica 2
RO - Romania 2
RS - Serbia 2
TW - Taiwan 2
AI - Anguilla 1
BA - Bosnia-Erzegovina 1
BG - Bulgaria 1
BM - Bermuda 1
BN - Brunei Darussalam 1
BO - Bolivia 1
BY - Bielorussia 1
BZ - Belize 1
DZ - Algeria 1
EE - Estonia 1
Totale 12.982
Salva come PNG Salva come JPEG
Città #
Dallas 1.405
Singapore 656
Hong Kong 552
Ashburn 483
Moscow 447
San Jose 427
Shanghai 225
Beijing 174
Council Bluffs 174
New York 153
Hefei 149
Milan 131
Lauterbourg 127
Princeton 101
Lawrence 98
Ho Chi Minh City 97
Phoenix 90
Los Angeles 77
Santa Clara 70
Rome 61
Hanoi 57
Nuremberg 56
São Paulo 54
Munich 44
Boardman 41
Warsaw 30
Montreal 28
Buffalo 27
Denver 27
Atlanta 25
Helsinki 24
Houston 24
Chennai 23
Dublin 23
Tokyo 23
Chicago 21
Orem 21
Boston 20
Brooklyn 20
Rio de Janeiro 20
Turku 20
Da Nang 19
Guangzhou 19
Naples 19
Vienna 19
Hangzhou 18
Poplar 17
Thessaloniki 17
London 16
Manchester 16
Brasília 15
Mexico City 15
Miano 15
Toronto 15
Frankfurt am Main 14
Lappeenranta 14
Seattle 13
Stockholm 13
Columbus 12
Johannesburg 12
Las Vegas 12
Porto Alegre 12
Baghdad 11
Belo Horizonte 11
San Francisco 11
Washington 11
Brussels 10
Curitiba 10
Monza 10
Philadelphia 10
Querétaro 10
Shenzhen 10
Turin 10
Amsterdam 9
Guarulhos 9
Guayaquil 9
Quito 9
Ribeirão Preto 9
Asunción 8
Biên Hòa 8
Cleveland 8
Dubai 8
Genoa 8
Haiphong 8
Oviedo 8
The Dalles 8
Wuxi 8
Bari 7
Brescia 7
Florianópolis 7
Jakarta 7
Kingston 7
Miami 7
Mumbai 7
Ninh Bình 7
Pittsburgh 7
Sydney 7
Zhengzhou 7
Buenos Aires 6
Cagliari 6
Totale 6.967
Salva come PNG Salva come JPEG
Nome #
Bcor loss promotes Richter transformation of chronic lymphocytic leukemia associated with Notch1 activation in mice: Lymphoma 467
Venetoclax-based regimens in octogenarian patients with CLL: efficacy, safety, and comparison to BTKi in a multicenter cohort 441
ATM aberrations in chronic lymphocytic leukemia: del(11q) rather than ATM mutations is an adverse-prognostic biomarker: CHRONIC LYMPHOCYTIC LEUKEMIA 439
Exploring Perceptions, Opinions, and Needs of Adult and Pediatric Cancer Patients, Caregivers, and Healthcare Professionals Towards Low-Fidelity Versions of the MyPal Project's Applications: Findings from 12 Pre-Pilot Focus Groups in 4 European Countries of an ePRO Intervention for Palliative Cancer Care (Preprint) 209
Outcomes in patients with chronic lymphocytic leukemia and TP53 aberration who received first-line ibrutinib: a nationwide registry study from the Italian Medicines Agency 187
A retinoic acid-dependent stroma-leukemia crosstalk promotes chronic lymphocytic leukemia progression 161
3D co-culture model of chronic lymphocytic leukemia bone marrow microenvironment predicts patient-specific response to mobilizing agents 159
Chronic lymphocytic leukaemia 137
A novel Rag2(-/-)gamma(-/-)(c)-xenograft model of human CLL 133
The evolving landscape of COVID-19 and post-COVID condition in patients with chronic lymphocytic leukemia: A study by ERIC, the European research initiative on CLL 124
Additional booster doses in patients with chronic lymphocytic leukemia induce humoral and cellular immune responses to SARS-CoV-2 similar to natural infection regardless ongoing treatments: A study by ERIC, the European Research Initiative on CLL 124
3D Bioprinting Allows the Establishment of Long-Term 3D Culture Model for Chronic Lymphocytic Leukemia Cells 122
Detection of clinically relevant variants in the TP53 gene below 10% allelic frequency: A multicenter study by ERIC, the European Research Initiative on CLL 120
Disrupting pro-survival and inflammatory pathways with dimethyl fumarate sensitizes chronic lymphocytic leukemia to cell death 120
Inhibition of chronic lymphocytic leukemia progression by full-length chromogranin A and its N-terminal fragment in mouse models 116
A novel ex vivo high-throughput assay reveals antiproliferative effects of idelalisib and ibrutinib in chronic lymphocytic leukemia 116
A First-in-human Study of Tenalisib (RP6530), a Dual PI3K δ/γ Inhibitor, in Patients With Relapsed/Refractory Hematologic Malignancies: Results From the European Study 115
Targeting the LYN/HS1 signaling axis in chronic lymphocytic leukemia 111
COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study 111
BTK and PLCG2 remain unmutated in one-third of patients with CLL relapsing on ibrutinib 107
IκBε deficiency accelerates disease development in chronic lymphocytic leukemia 106
Chronic Lymphocytic Leukemia with Mutated IGHV4-34 Receptors: Shared and Distinct Immunogenetic Features and Clinical Outcomes 105
EZN-2208 treatment suppresses chronic lymphocytic leukaemia by interfering with environmental protection and increases response to fludarabine 105
CLL-461 Humoral Response to COVID-19 Vaccine: A Challenge in CLL 104
Atezolizumab, venetoclax, and obinutuzumab combination in Richter transformation diffuse large B-cell lymphoma (MOLTO): a multicentre, single-arm, phase 2 trial 103
Bone Marrow Histopathology in the Diagnostic Evaluation of Splenic Marginal-zone and Splenic Diffuse Red Pulp Small B-cell Lymphoma: A Reliable Substitute for Spleen Histopathology? 101
HIF-1α regulates the interaction of chronic lymphocytic leukemia cells with the tumor microenvironment 101
PYK2 is overexpressed in chronic lymphocytic leukaemia: A potential new therapeutic target 100
A spheroid model that recapitulates the protective role of the lymph node microenvironment and serves as a platform for drug testing in chronic lymphocytic leukemia 100
T cell receptor gene repertoire profiles in subgroups of patients with chronic lymphocytic leukemia bearing distinct genomic aberrations 100
General population low-count CLL-like MBL persists over time without clinical progression, although carrying the same cytogenetic abnormalities of CLL. 100
In Vitro Sensitivity of CLL Cells to Fludarabine May Be Modulated by the Stimulation of Toll-like Receptors 100
A single-tube multiplex method for monitoring mutations in cysteine 481 of Bruton Tyrosine Kinase (BTK) gene in chronic lymphocytic leukemia patients treated with ibrutinib 99
Obinutuzumab plus chlorambucil versus ibrutinib in previously untreated chronic lymphocytic leukemia patients without TP53 disruptions: A real-life CLL campus study 98
Assessing Patients' Knowledge on Chronic Lymphocytic Leukemia: Validation of the ERIC CLL Knowledge Questionnaire in Greece 98
Lenalidomide enhances CD23.CAR T cell therapy in chronic lymphocytic leukemia 98
Clinical features, management, and prognosis of an international series of 161 patients with limited-stage diffuse large B-cell lymphoma of the bone (the IELSG-14 study) 96
MicroRNA and proliferation control in chronic lymphocytic leukemia: functional relationship between miR-221/222 cluster and p27 95
Invariant NKT cells contribute to chronic lymphocytic leukemia surveillance and prognosis 94
Targeting B-cell anergy in chronic lymphocytic leukemia. 92
Are we finally getting personal? Moving towards a personalized approach in chronic lymphocytic leukemia 91
XPO1 mutations identify early-stage CLL characterized by shorter time to first treatment and enhanced BCR signalling 90
Acalabrutinib in High-Risk Chronic Lymphocytic Leukaemia Naïve Patients: An Italian Multicenter Retrospective Observational Real-Life Experience 90
Interleukin-1 receptor-associated kinase 4 inhibitor interrupts toll-like receptor signalling and sensitizes chronic lymphocytic leukaemia cells to apoptosis 90
Thrombotic and bleeding complications in patients with chronic lymphocytic leukemia and severe COVID-19: a study of ERIC, the European Research Initiative on CLL 88
Olaptesed pegol (NOX-A12) with bendamustine and rituximab: a phase IIa study in patients with relapsed/refractory chronic lymphocytic leukemia 88
Management of chronic lymphocytic leukemia in Italy during a one year of the COVID-19 pandemic and at the start of the vaccination program. A Campus CLL report 88
Anti-CD20 rechallenge with ofatumumab in relapsed/refractory splenic marginal zone lymphoma: the MORE trial 87
MINIMAL RESIDUAL DISEASE-DRIVEN TREATMENT INTENSIFICATION WITH SEQUENTIAL ADDITION OF IBRUTINIB TO VENETOCLAX IN R/R CLL 87
Reprogramming cell death: BCL2 family inhibition in hematological malignancies 87
Outcomes of patients with hematologic malignancies and COVID-19: A systematic review and meta-analysis of 3377 patients 87
3D-STED Super-Resolution Microscopy Reveals Distinct Nanoscale Organization of the Hematopoietic Cell-Specific Lyn Substrate-1 (HS1) in Normal and Leukemic B Cells 86
Correction: Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status: a study by ERIC in HARMONY 85
Tailored approaches grounded on immunogenetic features for refined prognostication in chronic lymphocytic leukemia 84
COVID-19 and Chronic Lymphocytic Leukemia: Where We Stand Now 83
Clinical effect of stereotyped B-cell receptor immunoglobulins in chronic lymphocytic leukaemia: a retrospective multicentre study 83
Loss of CYLD promotes splenic marginal zone lymphoma 82
A phase II multi-center trial of pentostatin plus cyclophosphamide with ofatumumab in older previously untreated chronic lymphocytic leukemia patients 81
The functional in vitro response to CD40 ligation reflects a different clinical outcome in patients with chronic lymphocytic leukemia. 81
Real-world evidence on venetoclax in chronic lymphocytic leukemia: The Italian experience 81
Establishment and Characterization of PCL12, a Novel CD5+ Chronic Lymphocytic Leukaemia Cell Line 80
Clinical features, management and prognosis of multifocal primary bone lymphoma: A retrospective study of the international extranodal lymphoma study group (the IELSG 14 study) 78
Other malignancies in the history of CLL: an international multicenter study conducted by ERIC, the European Research Initiative on CLL, in HARMONY 78
Frontline treatment with the combination obinutuzumab ± chlorambucil for chronic lymphocytic leukemia outside clinical trials: Results of a multinational, multicenter study by ERIC and the Israeli CLL study group 78
Genetic and Phenotypic Attributes of Splenic Marginal Zone Lymphoma 78
MyPal-Child study protocol: An observational prospective clinical feasibility study of the MyPal ePRO-based early palliative care digital system in paediatric oncology patients 78
High rate of durable responses with undetectable minimal residual disease with front-line venetoclax and rituximab in young, fit patients with chronic lymphocytic leukemia and an adverse biological profile: results of the GIMEMA phase II LLC1518 – VERITAS study 77
Higher-order connections between stereotyped subsets: implications for improved patient classification in CLL 77
Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia 77
Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status: a study by ERIC in HARMONY 76
Dimethyl itaconate selectively targets inflammatory and metabolic pathways in chronic lymphocytic leukemia 76
CLL-like monoclonal B-cell lymphocytosis: are we all bound to have it? 76
Monoclonal B lymphocytosis in the general population 76
Trabectedin reveals a strategy of immunomodulation in chronic lymphocytic leukemia 75
Spontaneous regression in chronic lymphocytic leukaemia. Clinical features of 50 cases from the ERIC registry and review of the literature 74
Calreticulin as a novel B-cell receptor antigen in chronic lymphocytic leukemia 73
MyPal ADULT study protocol: A randomised clinical trial of the MyPal ePRO-based early palliative care system in adult patients with haematological malignancies 73
Distinct patterns of novel gene mutations in poor-prognostic stereotyped subsets of chronic lymphocytic leukemia: the case of SF3B1 and subset #2 72
Monoclonal B Cell Lymphocytosis in Hepatitis C Virus Infected Individuals 72
Dichotomous Toll-like receptor responses in chronic lymphocytic leukemia patients under ibrutinib treatment 72
Acalabrutinib: a highly selective, potent Bruton tyrosine kinase inhibitor for the treatment of chronic lymphocytic leukemia 72
Profiling the Genomic Landscape at the Early Stages of CLL: Low Genomic Complexity and Paucity of Driver Mutations in MBL and Indolent CLL 72
Fostering Palliative Care Through Digital Intervention: A Platform for Adult Patients With Hematologic Malignancies 70
Co-Designing Smartphone Notifications According to the Clinical Routine of Cancer Patients 70
Continuous venetoclax in treatment-naive TP53 disrupted patients with chronic lymphocytic leukemia: A chronic lymphocytic leukemia campus study 69
Different spectra of recurrent gene mutations in subsets of chronic lymphocytic leukemia harboring stereotyped B-cell receptors 69
Chronic lymphocytic leukemia management in Italy during the COVID-19 pandemic: A Campus CLL report 69
Relevance of Minimal Residual Disease in the Era of Targeted Agents 68
The non-canonical BAF chromatin remodeling complex is a novel target of spliceosome dysregulation in SF3B1-mutated chronic lymphocytic leukemia 67
Infrequent "chronic lymphocytic leukemia-specific" immunoglobulin stereotypes in aged individuals with or without low count monoclonal B cell lymphocytosis 67
T-Cell Dynamics in Chronic Lymphocytic Leukemia under Different Treatment Modalities 66
Clonal haematopoiesis as a risk factor for therapy-related myeloid neoplasms in patients with chronic lymphocytic leukaemia treated with chemo-(immuno)therapy 65
Highly similar genomic landscapes in monoclonal b-cell lymphocytosis and ultra-stable chronic lymphocytic leukemia with low frequency of driver mutations 64
Central nervous system involvement in CLL: an international retrospective study by ERIC, the European Research Initiative on CLL 63
No improvement in long-term survival over time for chronic lymphocytic leukemia patients in stereotyped subsets #1 and #2 treated with chemo(immuno)therapy 63
COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus 63
Computational analysis of the evolutionarily conserved Missing In Metastasis/Metastasis Suppressor 1 gene predicts novel interactions, regulatory regions and transcriptional control 63
Single cell analysis reveals immune dysfunction from the earliest stages of CLL that can be reversed by ibrutinib 63
Targeting macrophages sensitizes chronic lymphocytic leukemia to apoptosis and inhibits disease progression 62
Real-World Outcome of Treatment with Single-Agent Ibrutinib in Italian Patients with Chronic Lymphocytic Leukemia: Final Results of the EVIdeNCE Study 61
Totale 10.175
Salva come PNG Salva come JPEG
Categoria #
all - tutte 68.873
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 68.873
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/202275 0 0 0 21 6 3 8 19 7 6 2 3
2022/2023616 215 113 54 1 16 82 23 34 40 8 11 19
2023/2024477 13 20 27 119 22 71 4 27 1 12 44 117
2024/20252.285 276 53 63 60 87 164 243 215 393 340 182 209
2025/20268.036 544 1.018 1.057 992 542 191 555 487 1.798 375 221 256
2026/20271.713 254 649 442 368 0 0 0 0 0 0 0 0
Totale 13.296